Thin Film Electronics ASA
Oslo, 4 March 2021
This disclosure is sent on behalf of a certain large shareholder in Thin Film Electronics ASA (the "Company").
Reference is made to the announcement by the Company on 2 March 2021 regarding a successfully completed private placement in the Company and the subsequent issuance of 68,922,869 new shares following registration in the Norwegian Register of Business Enterprises. Due to the issuance of new shares in the Company, a certain large shareholder discloses the following information pursuant to Section 4-2 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations.
Upon registration, the shareholding of Middelborg Invest AS and close associates will represent 6.42% of the Company's total number of outstanding shares, holding a total of 71,248,487 shares in the Company. Furthermore, Middelborg Invest AS owns 17,993,008 Warrants B with an exercise price of NOK 0.25 per share and which will be exercisable at any time until 20 August 2021 and 37,416,667 Warrants C with an exercise price of NOK 0.25 per share and which will be exercisable at any time between 31 March 2021 and 30 June 2021. All unexercised Warrants will represent 4.99% of the Company's total number of outstanding shares. All shares and unexercised Warrants combined will represent 11.41% of the Company's total number of outstanding shares.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Evaxion17.10.2025 14:15:51 CEST | Press release
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
WillScot17.10.2025 14:00:00 CEST | Press release
WillScot Closes Amended and Extended Asset-Based Revolving Credit Facility
Novartis Pharma AG17.10.2025 14:00:00 CEST | Press release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
Sanofi Winthrop Industrie17.10.2025 13:05:00 CEST | Press release
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi Winthrop Industrie17.10.2025 13:00:00 CEST | Press release
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom